CD47 Blockade and Rituximab in Non-Hodgkin’s Lymphoma
CD47 Blockade and Rituximab in Non-Hodgkin’s Lymphoma
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
To the Editor:
Advani and colleagues (Nov. 1 issue)
1
report that the CD47-blocking antibody Hu5F9-G4 (hereafter, 5F9) had therapeutic efficacy in combination with rituximab in patients with lymphoma. On the basis of their preclinical studies,
2
the authors propose that 5F9 blocks CD47–SIRPα interactions and thereby improves tumor-ce...
Alternative Titles
Full title
CD47 Blockade and Rituximab in Non-Hodgkin’s Lymphoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2179500864
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2179500864
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMc1816156
